File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3350/cmh.2022.0087
- Scopus: eid_2-s2.0-85139869862
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis
Title | COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis |
---|---|
Authors | |
Keywords | Chronic hepatitis B COVID-19 Liver transplant Non-alcoholic fatty liver disease SARS-CoV-2 |
Issue Date | 4-Oct-2022 |
Publisher | Korean Association for the Study of the Liver |
Citation | Clinical and Molecular Hepatology, 2022, v. 28, n. 4, p. 890-911 How to Cite? |
Abstract | Background/Aims: Data of coronavirus disease 2019 (COVID-19) vaccine immunogenicity among chronic liver disease (CLD) and liver transplant (LT) patients are conflicting. We performed meta-analysis to examine vaccine immunogenicity regarding etiology, cirrhosis status, vaccine platform and type of antibody. Methods: We collected data via three databases from inception to February 16, 2022, and reported pooled seroconversion rate, T cell response and safety data after two vaccine doses. Results: Twenty-eight (CLD only: 5; LT only: 18; both: 2; LT with third dose: 3) observational studies of 3,945 patients were included. For CLD patients, seroconversion rate ranged between 84% (95% confidence interval [CI], 76-90%) and 91% (95% CI, 83-95%), based predominantly on neutralizing antibody and anti-spike antibody, respectively. Seroconversion rate was 81% (95% CI, 76-86%) in chronic hepatitis B, 96% (95% CI, 93-97%) in non-alcoholic fatty liver disease, 85% (95% CI, 75-91%) in cirrhosis and 85% (95% CI, 78-90%) in non-cirrhosis, 86% (95% CI, 78-92%) for inactivated vaccine and 89% (95% CI, 71-96%) for mRNA vaccine. The pooled seroconversion rate of anti-spike antibody was 66% (95% CI, 5575%) after two doses of mRNA vaccines and 88% (95% CI, 58-98%) after third dose among LT recipients. T cell response rate was 65% (95% CI, 30-89%). Prevalence of adverse events was 27% (95% CI, 18-38%) and 63% (95% CI, 39-82%) among CLD and LT groups, respectively. Conclusions: CLD patients had good humoral response to COVID-19 vaccine, while LT recipients had lower response. |
Persistent Identifier | http://hdl.handle.net/10722/331685 |
ISSN | 2021 Impact Factor: 8.337 2020 SCImago Journal Rankings: 1.420 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cheung, KS | - |
dc.contributor.author | Mok, CH | - |
dc.contributor.author | Mao, X | - |
dc.contributor.author | Zhang, R | - |
dc.contributor.author | Hung, IF | - |
dc.contributor.author | Seto, WK | - |
dc.contributor.author | Yuen, MF | - |
dc.date.accessioned | 2023-09-21T06:58:00Z | - |
dc.date.available | 2023-09-21T06:58:00Z | - |
dc.date.issued | 2022-10-04 | - |
dc.identifier.citation | Clinical and Molecular Hepatology, 2022, v. 28, n. 4, p. 890-911 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.uri | http://hdl.handle.net/10722/331685 | - |
dc.description.abstract | <p>Background/Aims: Data of coronavirus disease 2019 (COVID-19) vaccine immunogenicity among chronic liver disease (CLD) and liver transplant (LT) patients are conflicting. We performed meta-analysis to examine vaccine immunogenicity regarding etiology, cirrhosis status, vaccine platform and type of antibody.</p><p>Methods: We collected data via three databases from inception to February 16, 2022, and reported pooled seroconversion rate, T cell response and safety data after two vaccine doses.</p><p>Results: Twenty-eight (CLD only: 5; LT only: 18; both: 2; LT with third dose: 3) observational studies of 3,945 patients were included. For CLD patients, seroconversion rate ranged between 84% (95% confidence interval [CI], 76-90%) and 91% (95% CI, 83-95%), based predominantly on neutralizing antibody and anti-spike antibody, respectively. Seroconversion rate was 81% (95% CI, 76-86%) in chronic hepatitis B, 96% (95% CI, 93-97%) in non-alcoholic fatty liver disease, 85% (95% CI, 75-91%) in cirrhosis and 85% (95% CI, 78-90%) in non-cirrhosis, 86% (95% CI, 78-92%) for inactivated vaccine and 89% (95% CI, 71-96%) for mRNA vaccine. The pooled seroconversion rate of anti-spike antibody was 66% (95% CI, 5575%) after two doses of mRNA vaccines and 88% (95% CI, 58-98%) after third dose among LT recipients. T cell response rate was 65% (95% CI, 30-89%). Prevalence of adverse events was 27% (95% CI, 18-38%) and 63% (95% CI, 39-82%) among CLD and LT groups, respectively.</p><p>Conclusions: CLD patients had good humoral response to COVID-19 vaccine, while LT recipients had lower response.</p> | - |
dc.language | eng | - |
dc.publisher | Korean Association for the Study of the Liver | - |
dc.relation.ispartof | Clinical and Molecular Hepatology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Chronic hepatitis B | - |
dc.subject | COVID-19 | - |
dc.subject | Liver transplant | - |
dc.subject | Non-alcoholic fatty liver disease | - |
dc.subject | SARS-CoV-2 | - |
dc.title | COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis | - |
dc.type | Article | - |
dc.identifier.doi | 10.3350/cmh.2022.0087 | - |
dc.identifier.scopus | eid_2-s2.0-85139869862 | - |
dc.identifier.volume | 28 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | 890 | - |
dc.identifier.epage | 911 | - |
dc.identifier.issnl | 2287-2728 | - |